In early 2021, Hemophilia Federation of America surveyed members of the bleeding disorders community to gauge their response to the COVID-19 vaccine. The survey was conducted from January 22 to March 15, 2021. For the first half of this time frame, the Pfizer and Moderna vaccines were being administered; for the second half, the Johnson and Johnson vaccine became available.

At the time of the survey, 67% of responded had not been vaccinated, and over half of those indicated they are likely to receive the vaccination when eligible.

The top concerns among the bleeding disorders community about the COVID-19 vaccinations are:

  • Possible side effects
  • Safety of the vaccine
  • Getting an allergic reaction
  • Efficacy of the vaccine
  • Issues with intra-muscular injection for hemophilia patients
  • The rapid approval of the vaccine

Thirty-nine percent of respondents had not been vaccinated for the seasonal flu. Of those, nearly 60% said they were not likely or were very unlikely to get the flu vaccine.

Read our 2021 Survey Results here.


This survey was the second HFA conducted as a response to the COVID-19 pandemic. Results from the first survey can be found here.


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.